{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:44:57Z","timestamp":1780361097541,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00259-025-07368-y","type":"journal-article","created":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T21:16:16Z","timestamp":1750022176000},"page":"203-217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Divergent prognostic utility of metabolic risk scores in large B-cell lymphoma subtypes: a real-world analysis"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1100-5600","authenticated-orcid":false,"given":"Vibeke K. J.","family":"Vergote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. J. S.","family":"Woei-A-Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wies","family":"Deckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annouschka","family":"Laenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Tousseyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan","family":"Dierickx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe M.","family":"Deroose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"7368_CR1","doi-asserted-by":"crossref","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. Longo DL, editors. N Engl J Med. 2021;384:842\u201358.","DOI":"10.1056\/NEJMra2027612"},{"key":"7368_CR2","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB, de Berti O. E, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. Springer Nature; 2022. pp. 1720\u201348."},{"key":"7368_CR3","doi-asserted-by":"publisher","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229\u201353.\u00a0https:\/\/doi.org\/10.1182\/blood.2022015851","DOI":"10.1182\/blood.2022015851"},{"key":"7368_CR4","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800\u20138.","journal-title":"Blood"},{"key":"7368_CR5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"The international non","year":"1993","unstructured":"The international non-. Hodgkins lymphoma prognostic factors project. A predictive model for aggressive Non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329:987\u201394.","journal-title":"N Engl J Med"},{"key":"7368_CR6","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/blood.2019002729","volume":"135","author":"AS Ruppert","year":"2020","unstructured":"Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020;135:2041\u20138.","journal-title":"Blood"},{"key":"7368_CR7","doi-asserted-by":"publisher","unstructured":"Gleeson M, Counsell N, Cunningham D, Lawrie A, Clifton-Hadley L, Hawkes E et al. Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. Br J Haematol. 2021;192:1015\u20139.\u00a0https:\/\/doi.org\/10.1111\/bjh.16691","DOI":"10.1111\/bjh.16691"},{"key":"7368_CR8","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857\u201361.","journal-title":"Blood"},{"key":"7368_CR9","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW, Gordon LI, LaCasce AS, Crosby-Thompson A, et al. An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837\u201342.","journal-title":"Blood"},{"key":"7368_CR10","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","volume":"43","author":"NG Mikhaeel","year":"2016","unstructured":"Mikhaeel NG, Smith D, Dunn JT, Phillips M, M\u00f8ller H, Fields PA, et al. Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43:1209\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7368_CR11","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","volume":"41","author":"M Sasanelli","year":"2014","unstructured":"Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:2017\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7368_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejca.2019.09.027","volume":"124","author":"C Schmitz","year":"2020","unstructured":"Schmitz C, H\u00fcttmann A, M\u00fcller SP, Hanoun M, Boellaard R, Brinkmann M, et al. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial. Eur J Cancer. 2020;124:25\u201336.","journal-title":"Eur J Cancer"},{"key":"7368_CR13","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.3324\/haematol.2021.278663","volume":"107","author":"L Kostakoglu","year":"2022","unstructured":"Kostakoglu L, Mattiello F, Martelli M, Sehn LH, Belada D, Ghiggi C, et al. Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study. Haematologica. 2022;107:1633\u201342.","journal-title":"Haematologica"},{"key":"7368_CR14","doi-asserted-by":"publisher","unstructured":"Cheson BD. PET\/CT in lymphoma: current overview and future directions. Semin Nucl Med. 2018;48:76\u201381.\u00a0https:\/\/doi.org\/10.1053\/j.semnuclmed.2017.09.007","DOI":"10.1053\/j.semnuclmed.2017.09.007"},{"key":"7368_CR15","doi-asserted-by":"publisher","unstructured":"Frood R, Burton C, Tsoumpas C, Frangi AF, Gleeson F, Patel C. Baseline PET\/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review. [cited 2021 May 17]; Available from: https:\/\/doi.org\/10.1007\/s00259-021-05233-2","DOI":"10.1007\/s00259-021-05233-2"},{"key":"7368_CR16","doi-asserted-by":"crossref","unstructured":"Ceriani L, Milan L, Martelli M, Ferreri AJM, Cascione L, Zinzani PL et al. Metabolic heterogeneity on baseline 18FDG-PET\/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. Blood. 2018 [cited 2022 Feb 24];132:179\u201386.\u00a0https:\/\/ashpublications.org\/blood\/article\/132\/2\/179\/39226\/Metabolic-heterogeneity-on-baseline-18FDG-PET-CT","DOI":"10.1182\/blood-2018-01-826958"},{"key":"7368_CR17","doi-asserted-by":"crossref","unstructured":"Ceriani L, Martelli M, Zinzani PL, Ferreri AJM, Botto B, Stelitano C et al. Utility of baseline 18FDG-PET\/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood. 2015 [cited 2022 Feb 24];126:950\u20136.\u00a0https:\/\/ashpublications.org\/blood\/article\/126\/8\/950\/34706\/Utility-of-baseline-18FDG-PET-CT-functional","DOI":"10.1182\/blood-2014-12-616474"},{"key":"7368_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2967\/jnumed.119.229450","volume":"61","author":"AS Cottereau","year":"2020","unstructured":"Cottereau AS, Nioche C, Dirand AS, Clerc J, Morschhauser F, Casasnovas O, et al. 18F-FDG PET dissemination features in diffuse large B-Cell lymphoma are predictive of outcome. J Nucl Med. 2020;61:40\u20135.","journal-title":"J Nucl Med"},{"key":"7368_CR19","doi-asserted-by":"crossref","unstructured":"Cottereau AS, Meignan M, Nioche C, Capobianco N, Clerc J, Chartier L et al. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT\u2020. Ann Oncol. 2021 [cited 2022 Feb 7];32:404\u201311. https:\/\/pubmed.ncbi.nlm.nih.gov\/33278600\/","DOI":"10.1016\/j.annonc.2020.11.019"},{"key":"7368_CR20","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s00259-021-05480-3","volume":"49","author":"JJ Eertink","year":"2022","unstructured":"Eertink JJ, van de Brug T, Wiegers SE, Zwezerijnen GJC, Pfaehler EAG, Lugtenburg PJ, et al. 18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2022;49:932\u201342.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7368_CR21","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1007\/s00259-018-4041-0","volume":"45","author":"P Decazes","year":"2018","unstructured":"Decazes P, Becker S, Toledano MN, Vera P, Desbordes P, Jardin F, et al. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET\/CT is an independent prognostic factor of diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45:1672\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7368_CR22","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1200\/JCO.21.02063","volume":"40","author":"NG Mikhaeel","year":"2022","unstructured":"Mikhaeel NG, Heymans MW, Eertink JJ, de Vet HCW, Boellaard R, D\u00fchrsen U, et al. Proposed new dynamic prognostic index for diffuse large B-Cell lymphoma: international metabolic prognostic index. J Clin Oncol. 2022;40:2352\u201360.","journal-title":"J Clin Oncol"},{"key":"7368_CR23","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1182\/blood.2019003526","volume":"135","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Cottereau AS, Casasnovas O, Tilly H, Feugier P, Chartier L, et al. High total metabolic tumor volume at baseline predicts survival independent of response to therapy. Blood. 2020;135:1396\u2013405.","journal-title":"Blood"},{"key":"7368_CR24","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.1182\/bloodadvances.2021006923","volume":"6","author":"C Thieblemont","year":"2022","unstructured":"Thieblemont C, Chartier L, D\u00fchrsen U, Vitolo U, Barrington SF, Zaucha JM, et al. A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma. Blood Adv. 2022;6:5995\u20136004.","journal-title":"Blood Adv"},{"key":"7368_CR25","first-page":"3055","volume":"141","author":"JJ Eertink","year":"2023","unstructured":"Eertink JJ, Zwezerijnen GJC, Heymans MW, Pieplenbosch S, Wiegers SE, D\u00fchrsen U, et al. Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma. Blood. 2023;141:3055\u201364.","journal-title":"Blood"},{"key":"7368_CR26","first-page":"1","volume":"00","author":"VKJ Vergote","year":"2024","unstructured":"Vergote VKJ, Verhoef G, Janssens A, Sherida FJ, Woei-A-Jin H, Deckers W, et al. International metabolic prognostic index is superior to other metabolic tumor Volume-Based prognostication methods in a Real-Life cohort of diffuse large B-Cell lymphoma. J Nucl Med. 2024;00:1\u20138.","journal-title":"J Nucl Med"},{"key":"7368_CR27","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","volume":"34","author":"N Schmitz","year":"2016","unstructured":"Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, et al. CNS international prognostic index: A risk model for CNS relapse in patients with diffuse large B-Cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34:3150\u20136.","journal-title":"J Clin Oncol"},{"key":"7368_CR28","doi-asserted-by":"crossref","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification. J Clin Oncol Am Soc Clinical Oncol. 2014; 3059\u201367.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"7368_CR29","first-page":"328","volume-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J nucl med mol imaging","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J nucl med mol imaging. Berlin Heidelberg: Springer; 2015. pp. 328\u201354."},{"key":"7368_CR30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FE Harrell","year":"1996","unstructured":"Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361\u201387.","journal-title":"Stat Med"},{"key":"7368_CR31","doi-asserted-by":"crossref","unstructured":"Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG. Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration. J Natl Cancer Inst. Oxford University Press; 2018. pp. 803\u201311.","DOI":"10.1093\/jnci\/djy088"},{"key":"7368_CR32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275\u201382.","journal-title":"Blood"},{"key":"7368_CR33","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1182\/bloodadvances.2022008629","volume":"7","author":"JJ Eertink","year":"2023","unstructured":"Eertink JJ, Zwezerijnen GJC, Wiegers SE, Pieplenbosch S, Chamuleau MED, Lugtenburg PJ, et al. Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma. Blood Adv. 2023;7:214\u201323.","journal-title":"Blood Adv"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07368-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07368-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07368-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T05:05:42Z","timestamp":1764219942000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07368-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7368"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07368-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the Ethics Committee of University Hospitals\/KU Leuven (ref: S66824), and for all subjects the need for written informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"VKJV reports consultancy fees from Beigene, Cellgene, Gilead, Roche, Lilly Oncology, Abbvie, travel support from Amgen, Abbvie, Gilead, Roche and speaker fees from Janssen, Abbvie (paid to institution). CMD reports consultancy fees from: Sirtex, Advanced Accelerator Applications, Novartis, Ipsen, Terumo, PSI CRO and Immedica Pharma. Travel fees from: GE Healthcare, Sirtex (paid to institution). FJSHW reports consultancy fees from Takeda, Recordati (paid to institution). The other authors report no conflict of interest. DD has received honoraria from Takeda, Incyte, Sanofi, Novartis, Amgen, Atara Biotherapeutics, Kite\/Gilead and Pierre Fabre, all paid to his institution.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}